Navidea Biopharmaceuticals Announces Third-Party Asset Valuation Of Tc99m Tilmanocept For Indications In Rheumatoid Arthritis; Co. Reports ‘Under base-case assumptions that are discussed in the report, peak U.S. sales could reach $1B annually, and in the upside scenario peak could reach $1.8B’